Resumen

FERNANDEZ MONTEQUIN, José; MENA, Gabriela  y  SANTIESTEBAN, Llipsy. Treatment and recovery of Wagner 5 diabetic foot with Heberprot-P. Biotecnol Apl [online]. 2010, vol.27, n.2, pp. 113-115. ISSN 1027-2852.

To improve the quality of life of diabetic patients suffering from diabetic foot ulcers, and trying to diminish or avoid major amputations among them, we tested the use of Heberprot-P® (epidermal growth factor) in seventy of those patients having Wagner’s grade 5 diabetic foot. The product was administered by intralesional injection, three times a week. Twelve patients (17.1%) were amputated and seven (9%) abandoned the treatment. Otherwise, twenty eight patients (40%) saved their legs, and 23(32.8%) are currently being administered with 75 µg of Heberprot-P (EGF), with good results. Until this moment, Heberprot-P constitutes an answer for diabetic patients having diabetic foot grade 5 in the Wagner scale.

Palabras clave : Ischemic diabetic foot; human recombinant epidermal growth factor; diabetic foot Wagner 5; Wagner classification.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )